Adagrasib
- Generic Name
- Adagrasib
- Brand Names
- Krazati
- Drug Type
- Small Molecule
- Chemical Formula
- C32H35ClFN7O2
- CAS Number
- 2326521-71-3
- Unique Ingredient Identifier
- 8EOO6HQF8Y
- Background
Adagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations. However, the development of KRAS inhibitors has been challenging due to their high affinity for guanosine triphosphate (GTP) and guanosine diphosphate (GDP), ...
- Indication
Adagrasib is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
...
- Associated Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
- Associated Therapies
- -
Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)
- Conditions
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 79
- Registration Number
- NCT05840510
- Locations
- 🇺🇸
SCRI Oncology Partners, Nashville, Tennessee, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 68
- Registration Number
- NCT05673187
- Locations
- 🇮🇪
St James's Hospital, Dublin, Ireland
🇮🇪University Hospital Limerick, Limerick, Ireland
🇧🇪Instiute Jules Bordet, Brussels, Belgium
Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab
- Conditions
- Interventions
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2024-11-25
- Target Recruit Count
- 42
- Registration Number
- NCT05472623
- Locations
- 🇺🇸
Johns Hopkins, Baltimore, Maryland, United States
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Conditions
- Interventions
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 806
- Registration Number
- NCT04613596
- Locations
- 🇩🇪
Klinikum Kassel, Kassel, Germany
🇩🇪Klinikverbund Allgau - Klinikum Kempten, Kempten, Germany
🇩🇪Universitatsklinikum Schleswig-Holstein - Campus Lubeck, Lubeck, Germany
Safety and Efficacy Study of SAR442720 in Combination With Other Agents in Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 65
- Registration Number
- NCT04418661
- Locations
- 🇺🇸
~University of Texas - MD Anderson Cancer Center Site Number : 8400001, Houston, Texas, United States
🇨🇱Investigational Site Number : 1520002, Temuco, Chile
🇨🇳Investigational Site Number : 1580001, Taipei, Taiwan
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 186
- Registration Number
- NCT03994796
- Locations
- 🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸Henry Ford Saint John Hospital - Academic, Grosse Pointe Woods, Michigan, United States
🇺🇸Henry Ford Saint John Hospital - Breast, Grosse Pointe Woods, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.